Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Evaluate Forecasting Excellence

The Value of Outliers in Consensus Forecasting

  

A perspective on the portfolio strategy of the top 20 pharma companies

Evaluate Forecasting Excellence: The Value of Outliers in Consensus Forecasting analyses the portfolio strategy of the top 20 pharmaceutical companies by leveraging the maximum and minimum forecast within EvaluatePharma® consensus.

Themes of the report include:

  • Upside/downside radio metrics that identify companies that could either outperform in the coming years or are at risk.
  • Companies that could follow a different trajectory compared to the scenario outlined by consensus forecasts.
  • More details on the value of a company’s pipeline for which forecasts are not yet available.

The Value of Outliers in Consensus Forecasting is the first report in the  Evaluate Forecasting Excellence series which aims to improve forecasting accuracy to drive more robust decision-making, allocate investment more efficiently and ultimately drive continuous innovation.


Confirm your details on form below to download this report